Crescent Capital BDC, Inc. (FCRX)

NYSE: FCRX · Real-Time Price · USD · Preferred Stock
25.17
0.00 (0.00%)
At close: May 22, 2026
Market Cap418.94M -28.0%
Revenue (ttm)163.07M -13.8%
Net Income15.09M -69.5%
EPS0.41 -69.5%
Shares Out 36.85M
PE Ratio27.76
Forward PE7.58
Dividendn/a
Ex-Dividend Daten/a
Volume1,222
Open25.15
Previous Closen/a
Day's Range25.15 - 25.17
52-Week Range24.50 - 25.24
Beta0.64
Analystsn/a
Price Targetn/a
Earnings DateMay 13, 2026

About FCRX

Crescent Capital BDC, Inc. is as a business development company is a private equity / buyouts and loan fund. It specializes in directly investing. It specializes in middle market. The fund seeks to invest in United States.

Sector Financials
Founded 2015
Country United States
Stock Exchange NYSE
Ticker Symbol FCRX
Full Company Profile

News

Crescent Capital BDC price target lowered to $13 from $15 at BofA

BofA analyst Derek Hewett lowered the firm’s price target on Crescent Capital BDC (CCAP) to $13 from $15 and keeps a Buy rating on the shares. The firm is adjusting…

4 days ago - TheFly

Crescent Capital BDC Transcript: AGM 2026

The meeting confirmed quorum and proceeded with the election of two directors for terms expiring in 2029 and ratified Ernst & Young LLP as auditor for 2026. No shareholder questions were submitted during the session.

11 days ago - Transcripts

Crescent Capital BDC reduced fees a positive, says B. Riley

B. Riley keeps a Neutral rating on Crescent Capital BDC (CCAP) with a $13.50 price target following the “mixed” Q1 report. The biggest positive of the quarter is Crescent management…

11 days ago - TheFly

Crescent Capital BDC price target lowered to $15 from $16 at Ladenburg

Ladenburg analyst Christopher Nolan lowered the firm’s price target on Crescent Capital BDC (CCAP) to $15 from $16 and keeps a Buy rating on the shares.

11 days ago - TheFly

Crescent Capital BDC price target lowered to $12 from $13 at Wells Fargo

Wells Fargo analyst Finian O’Shea lowered the firm’s price target on Crescent Capital BDC (CCAP) to $12 from $13 and keeps an Equal Weight rating on the shares. The new…

11 days ago - TheFly

Crescent Capital BDC downgraded to Perform from Outperform at Oppenheimer

Oppenheimer last night downgraded Crescent Capital BDC (CCAP) to Perform from Outperform with a price target of $16, down from $19. The firm increased Crescent’s equity discount rate by 50…

11 days ago - TheFly

Crescent Capital BDC downgraded to Perform from Outperform at Oppenheimer

Oppenheimer downgraded Crescent Capital BDC (CCAP) to Perform from Outperform with a price target of $16, down from $19.

12 days ago - TheFly

Crescent Capital BDC Q1 Earnings Call Highlights

Crescent Capital BDC NASDAQ: CCAP reported a more difficult first quarter as higher non-accruals, lower base rates and broader credit-market volatility weighed on earnings and net asset value, prompti...

12 days ago - MarketBeat

Crescent Capital BDC Earnings Call Transcript: Q1 2026

NAV and NII declined due to increased non-accruals, especially in healthcare, but portfolio risk ratings remain stable. Management and incentive fees were reduced, the base dividend was reset, and Sun Life completed its acquisition of Crescent Capital.

12 days ago - Transcripts

Crescent Capital BDC Quarterly report: Q1 2026

Crescent Capital BDC has published its Q1 2026 quarterly earnings report on May 14, 2026.

12 days ago - Filings

Crescent Capital BDC Earnings release: Q1 2026

Crescent Capital BDC released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.

12 days ago - Filings

Crescent Capital BDC Slides: Q1 2026

Crescent Capital BDC has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 14, 2026.

12 days ago - Filings

Crescent Capital BDC declares 34c quarterly dividend, 9c special dividend

The company announced that its board of directors declared a second quarter regular cash dividend of 34c per share to stockholders of record as of June 30, payable on July…

13 days ago - TheFly

Crescent Capital BDC reports Q1 EPS 42c, consensus 41c

Reports Q1 NAV per share $18.27. The company said, “Subsequent to quarter end, the Company reduced its fee structure, lowering its base management fee from 1.25% to 1.00% and its…

13 days ago - TheFly

Crescent Capital BDC, Inc. Reports First Quarter 2026 Earnings Results; Declares a Second Quarter Base Dividend of $0.34 Per Share and Series of Special Dividends

LOS ANGELES, May 13, 2026 (GLOBE NEWSWIRE) -- Crescent Capital BDC, Inc. (“Crescent BDC” or the “Company”) (NASDAQ: CCAP) today reported net investment income of $0.42 per share and net income of ($0....

13 days ago - GlobeNewsWire

Crescent Capital BDC, Inc. Schedules Earnings Release and Conference Call to Discuss its First Quarter Ended March 31, 2026 Financial Results

LOS ANGELES, April 27, 2026 (GLOBE NEWSWIRE) -- Crescent Capital BDC, Inc. (“Crescent BDC”) (NASDAQ: CCAP) today announced it will release its financial results for the first quarter ended March 31, 2...

4 weeks ago - GlobeNewsWire

Crescent Capital BDC price target lowered to $15 from $15.50 at Keefe Bruyette

Keefe Bruyette analyst Paul Johnson lowered the firm’s price target on Crescent Capital BDC (CCAP) to $15 from $15.50 and keeps an Outperform rating on the shares. Published first on…

5 weeks ago - TheFly

Crescent Capital BDC Proxy statement: Proxy filing

Crescent Capital BDC filed a proxy statement on April 1, 2026, providing details for shareholder voting and corporate governance matters.

7 weeks ago - Filings

Crescent Capital BDC Proxy statement: Proxy filing

Crescent Capital BDC filed a proxy statement on April 1, 2026, providing details for shareholder voting and corporate governance matters.

7 weeks ago - Filings

Crescent Capital BDC initiated with a Neutral at B. Riley

B. Riley initiated coverage of Crescent Capital BDC (CCAP) with a Neutral rating and $13.50 price target Crescent has historically compared favorably to the business development company sector on cred...

2 months ago - TheFly

Crescent Capital BDC price target lowered to $13 from $14 at Wells Fargo

Wells Fargo analyst Finian O’Shea lowered the firm’s price target on Crescent Capital BDC (CCAP) to $13 from $14 and keeps an Equal Weight rating on the shares. The firm…

3 months ago - TheFly

Crescent Capital BDC Earnings Call Transcript: Q4 2025

Q4 2025 net investment income was $0.45 per share, covering the dividend, with NAV per share declining to $19.10 due to unrealized losses. Portfolio remains diversified and first lien-focused, while management reviews dividend and fee structure amid lower rates.

3 months ago - Transcripts

Crescent Capital BDC Annual report: Q4 2025

Crescent Capital BDC has published its Q4 2025 annual report on February 26, 2026.

3 months ago - Filings

Crescent Capital BDC Earnings release: Q4 2025

Crescent Capital BDC released its Q4 2025 earnings on February 26, 2026, summarizing the period's financial results.

3 months ago - Filings

Crescent Capital BDC Slides: Q4 2025

Crescent Capital BDC has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 26, 2026.

3 months ago - Filings